Search

Author/Creator Bayliffe, Andrew

1. An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension. (20th January 2022)

Authors:
Simon, Marc A.; Hanrott, Kate; Budd, David C.; Torres, Fernando; Grünig, Ekkehard; Escribano‐Subias, Pilar; Meseguer, Manuel L.; Halank, Michael; Opitz, Christian; Hall, David A.; Hewens, Deborah; Powley, William M.; Siederer, Sarah; Bayliffe, Andrew; Lazaar, Aili L.; Cahn, Anthony; Rosenkranz, S...
Journal:
Pulmonary circulation
Issue:
Volume 12:Number 1(2022)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury. Issue 8 (29th January 2018)

Authors:
Proudfoot, Alastair; Bayliffe, Andrew; O'Kane, Cecilia M; Wright, Tracey; Serone, Adrian; Bareille, Philippe Jean; Brown, Vanessa; Hamid, Umar I; Chen, Younan; Wilson, Robert; Cordy, Joanna; Morley, Peter; de Wildt, Ruud; Elborn, Stuart; Hind, Matthew; Chilvers, Edwin R; Griffiths, Mark; Summers,...
Journal:
Thorax
Issue:
Volume 73:Issue 8(2018)
Page Start:
723
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗